For Immediate Release

DIMERIX ANNOUNCES NEW BOARD MEMBER

MELBOURNE, Australia, 01 May 2023: Dimerix Limited (ASX: DXB) ("Dimerix" or the "Company"), a clinical-stage biopharmaceutical company with multiple late-stage clinical assets, is pleased to announce the appointment of a new non-executive director, Mr Clinton Snow, to the Board, effective 01 May 2023.

Mr Snow brings with him a wealth of experience from across the public and private sector. Mr Snow's skills and insights including in financial markets, investor relations, project management and corporate development and governance will be invaluable to the Board.

> "Dimerix is fortunate to be able to gain access to Clinton's extensive experience and networks. His appointment will bring a fresh perspective, diversity of thought and complementary experiences to the Dimerix Board at an important time for the company as we continue to execute on our Phase 3 clinical program, partnering discussions and other programs. The Board looks forward to his contribution to the future of the company."
>
> *Mr Hugh Alsop, Dimerix Non-Executive Director*

Mr Snow has nearly 20 years' experience as a technology leader across engineering management, project delivery, risk management, and assurance. Mr Snow is currently a non-executive director of iCetana Limited (ASX:ICE) and provides advisory services to a family office with multiple Australian biotech investments. Mr Snow holds a Bachelor of Chemical Engineering (honours) and Bachelor of Commerce degree from The University of Melbourne.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on **LinkedIn** and **Twitter**

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042.

In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a trial in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any trial, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease. DMX-200 is also under investigation as a potential treatment for acute respiratory distress syndrome (ARDS) in patients with COVID-19.

FSGS

FSGS is a rare disease that attacks the kidney's filtering units, where blood is cleaned (called the 'glomeruli'), causing irreversible scarring. This leads to permanent kidney damage and eventual end-stage failure of the organ, requiring dialysis or transplantation. For those diagnosed with FSGS the prognosis is not good. The average time from a diagnosis of FSGS to the onset of complete kidney failure is only five years and it affects both adults and children as young as two years old.[1] For those who are fortunate enough to receive a kidney transplant, approximately 60% will get re-occurring FSGS in the transplanted kidney.[2] At this time, there are no drugs specifically approved for FSGS anywhere in the world, so the treatment options and prognosis are poor.

The total global FSGS market was valued at US$12.6 billion in 2022,[3] with a CAGR of 8.2%, driven by approximately 220,000 FSGS sufferers across the 7 major markets[4] and premium orphan drug pricing[5]. Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX-200 in both the US and Europe for FSGS.[6] Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.[7]

References

1 *Guruswamy Sangameswaran KD, Baradhi KM. (2021) Focal Segmental Glomerulosclerosis), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/*

2 *Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669*

3 *DataBridge Market Research (2022) Global Focal Segmental Glomerulosclerosis Drugs Market – Industry Trends and Forecast to 2030; https://www.databridgemarketresearch.com/reports/global-focal-segmental-glomerulosclerosis-drugs-market*

4 *Delve Insight Market Research Report (2022): Focal segmental glomerulosclerosis (FSGS) – Market Insight, Epidemiology and market forecast – 2032; https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market*

5 *IQVIA Report (2018), Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments*

6 *ASX release 14Dec2015 and ASX release 21Nov2018*

7 *ASX release 29Jul2020*